PURE Bioscience Statistics
Total Valuation
PURE Bioscience has a market cap or net worth of 10.31 million. The enterprise value is 14.08 million.
| Market Cap | 10.31M |
| Enterprise Value | 14.08M |
Important Dates
The last earnings date was Monday, March 17, 2025.
| Earnings Date | Mar 17, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PURE Bioscience has 111.86 million shares outstanding. The number of shares has increased by 0.18% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 111.86M |
| Shares Change (YoY) | +0.18% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 41.26% |
| Owned by Institutions (%) | n/a |
| Float | 65.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.54 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.54 |
| EV / Sales | 7.56 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.65
| Current Ratio | 0.65 |
| Quick Ratio | 0.44 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.48 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -211.45% |
| Return on Invested Capital (ROIC) | -1,409.64% |
| Return on Capital Employed (ROCE) | 961.64% |
| Revenue Per Employee | 155,167 |
| Profits Per Employee | -258,333 |
| Employee Count | 12 |
| Asset Turnover | 2.24 |
| Inventory Turnover | 10.43 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -9.09% in the last 52 weeks. The beta is 0.33, so PURE Bioscience's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -9.09% |
| 50-Day Moving Average | 0.07 |
| 200-Day Moving Average | 0.08 |
| Relative Strength Index (RSI) | 67.70 |
| Average Volume (20 Days) | 71,584 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, PURE Bioscience had revenue of 1.86 million and -3.10 million in losses. Loss per share was -0.03.
| Revenue | 1.86M |
| Gross Profit | 1.09M |
| Operating Income | -2.81M |
| Pretax Income | -3.10M |
| Net Income | -3.10M |
| EBITDA | -2.73M |
| EBIT | -2.81M |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 202,000 in cash and 3.98 million in debt, giving a net cash position of -3.77 million or -0.03 per share.
| Cash & Cash Equivalents | 202,000 |
| Total Debt | 3.98M |
| Net Cash | -3.77M |
| Net Cash Per Share | -0.03 |
| Equity (Book Value) | -4.27M |
| Book Value Per Share | -0.04 |
| Working Capital | -304,000 |
Cash Flow
| Operating Cash Flow | -2.26M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 58.27%, with operating and profit margins of -150.81% and -166.49%.
| Gross Margin | 58.27% |
| Operating Margin | -150.81% |
| Pretax Margin | -166.49% |
| Profit Margin | -166.49% |
| EBITDA Margin | -146.78% |
| EBIT Margin | -150.81% |
| FCF Margin | n/a |
Dividends & Yields
PURE Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.18% |
| Shareholder Yield | -0.18% |
| Earnings Yield | -30.08% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on August 15, 2012. It was a reverse split with a ratio of 0.125.
| Last Split Date | Aug 15, 2012 |
| Split Type | Reverse |
| Split Ratio | 0.125 |
Scores
PURE Bioscience has an Altman Z-Score of -349.19. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -349.19 |
| Piotroski F-Score | n/a |